Mevion Medical Systems has secured 510(k) clearance from the US Food and Drug Administration (FDA) for S250i proton therapy system with Hyperscan pencil beam scanning (PBS) technology.

Mevion S250i is a compact proton therapy system that has the capacity to deliver conformal radiation therapy treatments with the support of Hyperscan pencil beam scanning technology.

Hyperscan PBS features layer switching and automated collimation systems, which help S250i system to deliver quicker and advanced PBS proton radiation treatments.

Pencil beam scanning systems will deliver the radiation dose by placing tumors spot-by-spot and layer-by-layer with sub-atomic particles.

 Hyperscan PBS uses a compact beam delivery path that will help to reduce delivery times to less than five seconds for some fields.

The PBS technology uses Adaptive Aperture proton multi-leaf collimator (pMLC) to cut edges of the beam at every layer of delivery.

Based on S250 series platform, the S250i system also features gantry mounted superconducting synchrocyclotron technology.

MedStar Georgetown University Hospital, which is located in Washington, D.C, is the first hospital to offer Hyperscan PBS technology.

Mevion Medical Systems CEO Joseph Jachinowski said: “The S250i system represents the next generation of intensity modulated proton therapy (IMPT) delivered in the most compact proton therapy platform.

“We are proud that the MEVION S250i system now has received both FDA clearance and CE mark. This is a very important milestone in our efforts to make precision proton therapy available to more patients in the fight against cancer.”

Based in Littleton of Massachusetts, Mevion Medical Systems provides proton therapy systems for use in radiation treatment for cancer patients.